EMD Serono

emdserono.com

Live pipeline data from ClinicalTrials.gov, refreshed daily.

Total trials

177

Active

19

Phase 3

45

Total enrollment

42,096

Pipeline matrix

Showing 29 of 29 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Avelumab15
Bevacizumab4
Enpatoran2
Standard of care2
Precemtabart tocentecan1
Trifluridine/Tipiracil1
Tuvusertib4
Tepotinib4
Niraparib3
M91402
M17742
Lartesertib2
M62232
Osimertinib1
Sacituzumab Govitecan1
NKTR-2551
Cemiplimab1
Capecitabine3
Pembrolizumab2
5-fluorouracil2
M94663
Folinic acid2
M35541
M03241
mFOLFIRINOX1
M74371
Abiraterone acetate1
Prednisone/Prednisolone1
Lenvatinib1

Next readouts

  • 2022-05-16
  • 2023-05-11
  • 2025-06-20
  • 2026-02-11
  • 2026-06-14
  • 2026-07-30
  • 2026-08-21
  • 2026-09-30
  • 2026-10-23
  • 2027-01-14

Top conditions

  • Multiple Sclerosis18
  • Advanced Solid Tumor10
  • Solid Tumors8
  • Advanced Solid Tumors6
  • Ovarian Cancer6
  • Colorectal Cancer4
  • Carcinoma, Non-Small-Cell Lung4
  • Relapsing Multiple Sclerosis4

Frequently asked questions about EMD Serono

How many clinical trials does EMD Serono have on ClinicalTrials.gov?
EMD Serono is listed as the lead sponsor on 177 clinical trials in ClinicalTrials.gov, 19 of which are currently active (recruiting, enrolling, or ongoing).
How many of EMD Serono's trials are in Phase 3?
45 of EMD Serono's trials are in Phase 3, spread across 29 active drug programs.
What therapeutic areas does EMD Serono focus on?
EMD Serono's most-studied conditions on ClinicalTrials.gov are Multiple Sclerosis, Advanced Solid Tumor, Solid Tumors, Advanced Solid Tumors, Ovarian Cancer.
When are EMD Serono's next clinical trial readouts?
EMD Serono has 10 upcoming primary-completion readouts tracked here; the soonest is “Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)”, expected around 2022-05-16.